COMPANY

Tenaya Therapeutics

HQ: South San Francisco, CA source · tenayatherapeutics.com ↗ · West Coast

Keywords: gene therapy arrhythmogenic right ventricular cardiomyopathy AAV heart disease Hypertrophic Cardiomyopathy TN-201 TN-401

Location: South San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Dec 11, 2025 Raise Follow-on offering: $60M (total, as published), announced Dec 11, 2025. Source: SEC filing. source ↗
Mar 3, 2025 Raise Follow-on offering: $52.5M (total, as published), announced Mar 3, 2025. Source: SEC filing. source ↗
Feb 3, 2025 Grant Government grant: $8M (total, as published), announced Feb 3, 2025. Source: company release on GlobeNewswire. source ↗
Mar 26, 2024 Trial start Phase 1: Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC source ↗
Aug 10, 2023 Trial start Phase 1/Phase 2: Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM source ↗
Jan 31, 2023 Trial start —: Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associat source ↗
Nov 1, 2021 Trial start —: Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy source ↗

2027-08 (ESTIMATED) · Phase 1/Phase 2 · Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM · NCT05836259
2028-06 (ESTIMATED) · · Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy · NCT05112237
Mar 29, 2030 (ESTIMATED) · · Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated · NCT06311708

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $112.5M. Last 2 years.

Dec 11, 2025 Follow-on offering: $60M (total, as published), announced Dec 11, 2025. Source: SEC filing. source ↗
Mar 3, 2025 Follow-on offering: $52.5M (total, as published), announced Mar 3, 2025. Source: SEC filing. source ↗
Feb 3, 2025 Government grant: $8M (total, as published), announced Feb 3, 2025. Source: company release on GlobeNewswire. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT05112237	Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy	Not listed	Active, not recruiting	Nov 1, 2021	2028-06 (estimated)
NCT05836259	Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM	Phase 1/Phase 2	Recruiting	Aug 10, 2023	2027-08 (estimated)
NCT06228924	Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC	Phase 1	Recruiting	Mar 26, 2024	May 1, 2026 (estimated)
NCT06311708	Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)	Not listed	Recruiting	Jan 31, 2023	Mar 29, 2030 (estimated)